Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PN-152, 243/PN-196, 444 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| PN-152,243)/PN-196,444 | DRUG | - |
Inclusion Criteria: * Patients must be newly diagnosed with moderate or high-grade sarcoma and be receiving AI (Adriamycin/Ifosfamide) chemotherapy Exclusion Criteria: * Patients must not have active bleeding (exclusions do apply) or history of platelet disorder
Top 20 of 27 competitors
PN-152,243/PN-196,444 is an investigational small molecule developed by Pfizer, Inc. (PFE) for use in sarcoma. It was studied in a Phase 3 trial for the prevention of thrombocytopenia, a condition of low platelet count, in patients with sarcoma. It is not described as approved.
PN-152,243/PN-196,444 was studied in sarcoma for the prevention of thrombocytopenia. The Phase 3 trial NCT00038311 evaluated its safety and efficacy in preventing low platelet counts in sarcoma patients. The study enrolled 120 participants and has been completed.
PN-152,243/PN-196,444 is developed by Pfizer, Inc., which trades under the ticker PFE. Pfizer sponsored the Phase 3 trial of this small molecule in sarcoma for the prevention of thrombocytopenia.
PN-152,243/PN-196,444 is in Phase 3 development. One Phase 3 trial, NCT00038311, has been completed. No active trials are ongoing. The drug is investigational and has not been stated as approved by the FDA.
PN-152,243/PN-196,444 was evaluated in one Phase 3 clinical trial, NCT00038311, titled Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia. The trial enrolled 120 participants with sarcoma in the United States and has been completed.